APA (7th ed.) Citation

Moreau, P., Pylypenko, H., Grosicki, S., Karamanesht, I., Leleu, X., Grishunina, M., . . . Harousseau, J. (2011). Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: A randomised, phase 3, non-inferiority study. Lancet Oncology, 12(5), 431. https://doi.org/10.1016/S1470-2045(11)70081-X

Chicago Style (17th ed.) Citation

Moreau, Philippe, et al. "Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma: A Randomised, Phase 3, Non-inferiority Study." Lancet Oncology 12, no. 5 (2011): 431. https://doi.org/10.1016/S1470-2045(11)70081-X.

MLA (9th ed.) Citation

Moreau, Philippe, et al. "Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma: A Randomised, Phase 3, Non-inferiority Study." Lancet Oncology, vol. 12, no. 5, 2011, p. 431, https://doi.org/10.1016/S1470-2045(11)70081-X.